A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients

Completed · Phase 3 · Has a placebo group

Conditions studied: Colonoscopy

In brief

A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open-label arm for midazolam, in patients undergoing a colonoscopy for diagnostic or therapeutic reasons.

Key facts

Study ID

NCT02290873

Run by

Paion UK Ltd.

People needed

461

Starts

2015-03-30

Expected to finish

2016-04-19

Last updated by the study team

2020-10-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients, aged ≥18, scheduled to undergo a diagnostic or therapeutic colonoscopy (therapeutic procedures could include hemostasis, resection, ablation decompression, foreign body extraction, for example).
• American Society of Anesthesiologists Score 1 through 3
• Body mass index ≤40 kg/m2.
• For female patients with child-bearing potential, negative result of pregnancy test (serum or urine) as well as use of birth control during the study period (from the time of consent until all specified observations were completed).
• Patient voluntarily signed and dated an informed consent form that was approved by an Independent Review Board prior to the conduct of any study procedure.
• Patient was willing and able to comply with study requirements and return for a Follow-up Visit on Day 4 (+3/-1 days) after the colonoscopy.

You may not qualify if…

• Patients with a known sensitivity to benzodiazepines, flumazenil, opioids, naloxone, or a medical condition such that these agents were contraindicated.
• Chronic use of benzodiazepines for any indication (eg, insomnia, anxiety, spasticity).
• Chronic use of opioids for any indication.
• Female patients with a positive serum human chorionic gonadotropin pregnancy test at screening or baseline.
• Lactating female patients.
• Patients with positive drugs of abuse screen or a positive serum ethanol at baseline.
• Patient with a history of drug or ethanol abuse within the past 2 years.
• Patients in receipt of any investigational drug within 30 days or less than seven half-lives (whichever was longer) before screening, or scheduled to receive one during the study period.
• Participation in any previous clinical trial with remimazolam.
• Patients with an inability to communicate well in English with the investigator, or deemed unsuitable according to the investigator (in each case providing a reason).

Where it is running

• University of South Alabama — Mobile, Alabama, United States
• Advanced Clinical Research Institute — Anaheim, California, United States
• Precision Research Institute — Chula Vista, California, United States
• Precision Research Institute — San Diego, California, United States
• Borland-Grover Clinic, P.A — Jacksonville, Florida, United States
• Indiana University Health — Indianapolis, Indiana, United States
• Delta Research Partners Inc — Monroe, Louisiana, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Wake Research Associates — Raleigh, North Carolina, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Thomas Jefferson Medical College — Philadelphia, Pennsylvania, United States
• Nashville Medical Research Institute — Nashville, Tennessee, United States
• Gastroenterology Associates of Tidewater — Chesapeake, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.